April 12, 2024 — Bayer and Hologic, Inc. announced a first-of-its-kind collaboration to deliver a coordinated solution for contrast-enhanced mammography (CEM). The two companies will showcase the solution at the annual Society of Breast Imaging Symposium from April 11-14, 2024 in Montreal, Canada.
Contrast-enhanced mammography is a sensitive and relatively low-cost breast imaging modality that can be used to support breast cancer diagnosis and help to guide treatment.1 The offering brings together Hologic’s leading mammography technologies and Bayer’s leading contrast-enhanced mammography contrast delivery system, the MEDRAD Stellant FLEX Computed Tomography (CT) Injection System. The MEDRAD Stellant FLEX CT Injection System with Certegra Workstation is the first and only CT injection system 510(k) cleared with an additional contrast-enhanced mammography application. By working together, Hologic and Bayer are streamlining the purchasing process for radiologists and imaging facilities, providing a seamless set-up and ongoing, supportive educational resources.
"We are thrilled to work with Hologic to increase access to this emerging breast imaging modality,” said Sven Schmidt, Head of Region Americas Radiology at Bayer. “Together we will deliver an innovative and coordinated solution for both patients and healthcare professionals alike.”
About Breast Cancer and Contrast-Enhanced Mammography
The American Cancer Society estimates that approximately 310,720 new cases of invasive breast cancer will be diagnosed in women in 2024 and approximately 42,250 women will die.2
Contrast-enhanced mammography is a breast imaging modality and the value of contrast-enhanced mammography as an adjunct to mammography is affirmed by an increasing number of independent scientific publications. Contrast-enhanced mammography can be performed as part of an everyday clinical practice and used in various clinical settings, such as inconclusive findings in previous imaging procedures.
For more information: www.bayer.com
Find more SBI24 conference coverage here
References:
1 Covington MF. Contrast-Enhanced Mammography Implementation, Performance, and Use for Supplemental Breast Cancer Screening. Radiol Clin North Am. 2021 Jan;59(1):113-128. doi: 10.1016/j.rcl.2020.08.006. Epub 2020 Oct 29. PMID: 33222993.
2 Key Statistics for Breast Cancer. American Cancer Society. https://www.cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html#:~:text=The%20American%20Cancer%20Society's%20estimates,will%20die%20from%20breast%20cancer. Last Revised: January 17, 2024. Accessed March 18, 2024.
October 24, 2025 
